Therapeutical proteins can train our immune system (Vaccines), correct protein defects/dysfunctions (Protein Replacement Therapies), cell programming (CAR-T), and so on. mRNA is a revolutionary way to make therapeutical proteins by the body themselves, which opens new avenues for preventing, treating and curing diseases. The 2023 Nobel Prize in Medicine or Physiology was awarded to mRNA pioneers.
In therapeutical era, the "half-life" of mRNA is matter, mRNAs need to reach its effective concentration window to achieve desired efficacy. Linear mRNA is intrinsically unstable due to free ends which are sensitive to RNA degradation enzymes, so its "half-life" is short, which largely limits the therapeutical potentials of linear mRNA. Circular mRNA is a kind of "circle" format mRNA without ends so intrinsically stable in the body. This unique feature empowered circular mRNA in developing mRNA therapeutics. The Nature said that circular RNA could be the next big thing for RNA therapeutics.
Byterna is a leading company focusing on cmRNA therapeutics R&D. We developed a series of proprietary cmRNA technologies to unleash the full potentials of cmRNA therapeutics, including scarless circularization, circular RNA modification, cmRNA AI design, targeted LNP delivery, etc. These advanced technologies enable potential "First-in-Class" and "Best-in-Class" pipelines in our portfolio.
HSP®
byteModi®
